The Influence of Daily Intake of Whole Grain Barley or Oats on Biomarkers of Cardiovascular Disease
13. oktober 2011 oppdatert av: United States Department of Agriculture (USDA)
The objectives of this study are the following: 1) to determine the effect of daily consumption of whole grain barley for six week on risk factors of cardiovascular disease compared to a diet low in whole grains, and 2) to compare the effects of daily consumption of whole grain barley to those of whole grain oats for six weeks to determine if the response to these two grains is different.
Studieoversikt
Status
Fullført
Forhold
Intervensjon / Behandling
Studietype
Intervensjonell
Registrering (Forventet)
69
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Maryland
-
Beltsville, Maryland, Forente stater, 20705
- USDA Beltsville Human Nutrition Research Center
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
25 år til 70 år (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- Men and women between the ages of 25-70 years
- Body mass index (BMI) ≥ 19 and ≤ 38
- Willingness and ability to make scheduled appointments at clinical site as required by study protocol
Exclusion Criteria:
- Do not regularly consume breakfast or dislike cereal for breakfast
- Known (self-reported) allergy or adverse reaction to grains (e.g., wheat, gluten, barley)
- Presence of kidney disease, liver disease, gout, untreated or unstable hypothyroidism, untreated or unstable hyperthyroidism, certain cancers, gastrointestinal disease, pancreatic disease, other metabolic diseases, or malabsorption syndromes
- Type 2 diabetes requiring the use of oral antidiabetic agents or insulin
- Fasting triglycerides > 300 mg/dL
- Fasting glucose > 126 mg/dL
- Use of cholesterol lowering medication
- Blood pressure > 180/100 or hypertension treated with calcium channel blockers, direct acting vasodilators, or beta blockers
- History of bariatric or certain other surgeries related to weight control
- History of major surgery within 3 months of enrollment
- Smokers or other tobacco users (during 6 months prior to the start of the study)
- Antibiotic use during the intervention or for 3 months prior to the intervention period
- History of eating disorders or other dietary patterns which are not consistent with the dietary intervention (e.g., vegetarians, very low fat diets, high protein diets)
- Volunteers who have lost 10% of body weight within the last 6 months
- Unable or unwilling to give informed consent or communicate with study staff
- Self-report of alcohol or substance abuse within the past 12 months and/or current acute treatment or rehabilitation program for these problems (long-term participation in Alcoholics Anonymous is not an exclusion)
- Other medical, psychiatric, or behavioral factors that in the judgment of the Principal Investigator may interfere with study participation or the ability to follow the intervention protocol
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Trippel
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Whole Grain Barley Diet
A controlled diet containing at least 4 daily servings of whole grain barley.
|
Subjects will be randomly assigned to one of three treatments: 1) a control diet containing 0.7 daily servings of whole grain, 2) a diet containing at least 4 daily servings of whole grain barley or 3) a diet containing at least 4 servings of whole grain oats.
After 6 weeks, risk factors of cardiovascular disease will be assessed after a 12 hr fast.
During the seventh week, risk factors of cardiovascular disease will be assessed in the postprandial state.
|
|
Aktiv komparator: Whole Grain Oats Diet
A diet containing at least 4 servings of whole grain oats.
|
Subjects will be randomly assigned to one of three treatments: 1) a control diet containing 0.7 daily servings of whole grain, 2) a diet containing at least 4 daily servings of whole grain barley or 3) a diet containing at least 4 servings of whole grain oats.
After 6 weeks, risk factors of cardiovascular disease will be assessed after a 12 hr fast.
During the seventh week, risk factors of cardiovascular disease will be assessed in the postprandial state.
|
|
Annen: Low Whole Grain Diet
A control diet containing 0.7 daily servings of whole grain.
|
Subjects will be randomly assigned to one of three treatments: 1) a control diet containing 0.7 daily servings of whole grain, 2) a diet containing at least 4 daily servings of whole grain barley or 3) a diet containing at least 4 servings of whole grain oats.
After 6 weeks, risk factors of cardiovascular disease will be assessed after a 12 hr fast.
During the seventh week, risk factors of cardiovascular disease will be assessed in the postprandial state.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Meal Tolerance Assessment
Tidsramme: 7 hours
|
Subjects will provide a baseline blood sample at 15 minutes and 5 minutes prior to consuming a test meal.
Subjects will then consume a high fat breakfast of foods such as eggs, buttered English muffins, and donuts.
Blood samples will be collected 30, 60, 90, 120, 150, 180, 210, 240, 270, 300, 360, and 420 min following ingestion of the test meal.
Measurements will be made for serum triglyceride area under the curve, serum cholesterol, insulin, glucose, and plasma apo B48.
|
7 hours
|
|
Biomarkers of cardiovascular risk
Tidsramme: After a 12 hour fast
|
Fibrinogen, factor VII, blood pressure, total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides, Lp(a), and lipoprotein size.
|
After a 12 hour fast
|
|
Biomarkers of oxidative stress
Tidsramme: After 6 weeks of feeding
|
Nitrites and nitrates, malondialdehyde, lipid hydroperoxides, ox-LDL, resistance of LDL to Cu2+-induced oxidation, FRAP, glutathione, glutathione-S-transferase, super oxide dismutase, PON-1, betaine, homocysteine, total thiols, urinary isoprostanes.
|
After 6 weeks of feeding
|
|
Biomarkers of inflammation
Tidsramme: After 6 weeks of controlled feeding
|
C-reactive protein (CRP), IL-6, IL-8, IL-10, IL-18, TNFα, matrix metalloproteinases (MMP-2, MMP-9), e-Selectin, ICAM, VCAM
|
After 6 weeks of controlled feeding
|
|
Biomarkers of glucoregulatory control
Tidsramme: After 6 weeks of feeding
|
Glycated apolipoprotein B, hemoglobin A1c, fructosamine, insulin, glucose, leptin, adiponectin
|
After 6 weeks of feeding
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Genotype testing
Tidsramme: After 6 weeks of controlled feeding
|
Blood will be used to test for genetic traits that may influence nutrient metabolism and also traits reflecting the mechanisms that may be influenced by the intervention.
|
After 6 weeks of controlled feeding
|
|
Microarray and targeted gene expression testing
Tidsramme: After 6 weeks of controlled feeding
|
Blood samples will be used to test how the intervention affects gene expression.
Global gene expression will be performed for a complete survey of the RNA response to the intervention.
Targeted gene expression will be performed to confirm the findings of the global gene expression analysis.
|
After 6 weeks of controlled feeding
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Janet A Novotny, PhD, USDA Beltsville Human Nutrition Research Center
Publikasjoner og nyttige lenker
Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.
Hjelpsomme linker
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart
1. mai 2011
Primær fullføring (Faktiske)
1. august 2011
Studiet fullført (Faktiske)
1. august 2011
Datoer for studieregistrering
Først innsendt
8. februar 2011
Først innsendt som oppfylte QC-kriteriene
9. februar 2011
Først lagt ut (Anslag)
10. februar 2011
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
14. oktober 2011
Siste oppdatering sendt inn som oppfylte QC-kriteriene
13. oktober 2011
Sist bekreftet
1. oktober 2011
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- HS34
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .